1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
Academic and Community Cancer Research UnitedPhase 2 NCT04117945 Registry history of NCT04117945 on ClinicalTrials.gov (opens the registry)
Changed
| Phase 2 | 12 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 2 | ||||
| NCT05168163 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of… | Locally Advanced Hepatocellular Carcinoma | Recruiting | 2026-08-04 |
| NCT06160206 | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of… | Recurrent Glioblastoma | Recruiting | 2024-11-19 |
| NCT05910801 | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory… | Recurrent Mantle Cell Lymphoma | Recruiting | 2024-11-18 |
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete… | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recruiting | 2024-09-26 |
| NCT03233347 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating… | Ann Arbor Stage I Hodgkin Lymphoma | Active, Not Recruiting | 2026-09-15 |
| NCT04756401 | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk… | Recurrent Plasma Cell Myeloma | Active, Not Recruiting | 2026-09-15 |
| NCT04626791 | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of… | Mantle Cell Lymphoma | Active, Not Recruiting | 2026-08-25 |
| NCT05194293 | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | Stage IB Hepatocellular Carcinoma AJCC v8 | Active, Not Recruiting | 2026-07-20 |
| NCT03012100 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in… | Bilateral Breast Carcinoma | Active, Not Recruiting | 2026-06-30 |
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA… | Bile Duct Adenocarcinoma | Active, Not Recruiting | 2026-05-15 |
| NCT05246670 | PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy | Chemotherapy-Induced Peripheral Neuropathy | Active, Not Recruiting | 2025-09-22 |
| NCT02758717 | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin… | Ann Arbor Stage IB Hodgkin Lymphoma | Active, Not Recruiting | 2025-09-09 |
Non-Hodgkin Lymphoma (3) · Hodgkin Lymphoma (2) · Liver Cancer (2) · Mantle Cell Lymphoma (2) · Breast Cancer (1) · Cholangiocarcinoma (1) · DLBCL (1) · Glioblastoma (1) · Glioma (1) · Multiple Myeloma (1)